Compare Cronos Group Inc (CRON) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs iShares MSCI India ETF — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while iShares MSCI India ETF trades at $50.05. The key difference: Cronos Group Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| CRON | INDA | |
|---|---|---|
Market Cap | $1.11B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $3.27 | $55.29 |
52-Week Low | $2.30 | $45.42 |
Enterprise Value | $310.67M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
INDA, trading at $50.39 with a 0.54% daily gain, shows a bullish technical outlook supported by moving averages, though RSI levels indicate potential overbought conditions near-term. The ETF tracks India's equity market, the world's fastest-growing large economy, which expanded 7.8% in Q1 2026 (CNBC, June 5, 2026). Recent news highlights foreign capital rotation away from AI-heavy Asian markets, with India facing sector-specific headwinds in pharmaceuticals and IT.
The outlook remains positive given India's robust economic growth, but risks include U.S. tariff uncertainty, Middle East shipping disruptions impacting exports (Reuters, August 4, 2026), and El Niño monsoon concerns. Investor sentiment is mixed amid foreign outflows, yet structural growth opportunities support long-term potential. Key watchpoints are earnings delivery from underlying holdings and macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
